Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nε-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection

Journal of Virology

Volumn 79, Issue 24, 2005, Pages 15289-15301

  Zhang, Xiuli ^a   Issagholian, Annie ^a   Berg, Eric A ^a   Fishman, Jordan B ^a   Nesburn, Anthony B ^a   BenMohamed, Lbachir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN B; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LIPID; LYSINE DERIVATIVE; N EPSILON PALMITOYLLYSINE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EYE INFECTION; FEMALE; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS 1; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EPITOPES; EYE INFECTIONS, VIRAL; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; LYSINE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1;

EID: 29744451544     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.24.15289-15301.2005     Document Type: Article

References (43)

1. Banks, T. A., S. Nair, and B. T. Rouse. 1993. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. J. Virol. 67:613-616.
2. BenMohamed, L, Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32:2274-2281.
3. BenMohamed, L., G. Bertrand, C. D. McNamara, H. Gras-Masse, J. Hammer, S. L. Wechsler, and A. B. Nesburn. 2003. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77:9463-9473.
4. BenMohamed, L., H. Gras-Masse, A. Tartar, P. Daubersies, K. Brahimi, M. Bossus, A. Thomas, and P. Druilhe. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242-1253.
5. BenMohamed, L., R. Krishnan, C. Auge, J. F. Primus, and D. J. Diamond. 2002. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106:113-121.
6. BenMohamed, L., R. Krishnan, J. Longmate, C. Auge, L. Low, J. Primus, and D. J. Diamond. 2000. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum. Immunol. 61:764-779.
7. BenMohamed, L., A. Thomas, M. Bossus, K. Brahimi, J. Wubben, H. Gras-Masse, and P. Druilhe. 2000. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18:2843-2855.
8. BenMohamed, L., A. Thomas, and P. Druilhe. 2004. Long-term multiepitopic cytotoxic T lymphocytes induced in chimpanzees by combinations of Plasmodium falciparum liver stage peptides and lipopeptides. Infect. Immun. 72:11-19.
9. BenMohamed, L., S. L. Wechsler, and A. B. Nesburn. 2002. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect. Dis. 2:425-431.
10. Berzofsky, J. A., J. D. Ahlers, M. A. Derby, C. D. Pendleton, T. Arichi, and I. M. Belyakov. 1999. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol. Rev. 170:151-172.
11. Blaney, J. E., Jr., E. Nobusawa, M. A. Brehm, R. H. Bonneau, L. M. Mylin, T. M. Fu, Y. Kawaoka, and S. S. Tevethia. 1998. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 72:9567-9574.
12. Bourel-Bonnet, L., D. Bonnet, F. Malingue, H. Gras-Masse, and O. Melnyk. 2003. Simultaneous lipidation of a characterized peptide mixture by chemoselective ligation. Bioconjug. Chem. 14:494-499.
13. Brynestad, K., B. Babbit, L. Huang, and B. T. Rouse. 1990. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J. Virol. 64:680-685.
14. Ciupitu, A. M., M. Petersson, C. L. O'Donnell, K. Williams, S. Jindal, R. Kiessling, and R. M. Welsh. 1998. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685-691.
15. Dana, M. R., Y. Qian, and P. Hamrah. 2000. Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 19:625-643.
16. +-T-cell epitopes recognized. J. Virol. 77:11220-11231.
17. + T cell response. J. Exp. Med. 187:341-348.
18. Gras-Masse, H. 2001. Chemoselective ligation and antigen vectorization. Biologicals 29:183-188.
19. Hanke, T., F. L. Graham, K. L. Rosenthal, and D. C. Johnson. 1991. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. J. Virol. 65:1177-1186,
20. Hosmalin, A., M. Andrieu, E. Loing, J. F. Desoutter, D. Hanau, H. Gras-Masse, A. Dautry-Varsat, and J. G. Guillet. 2001. Lipopeptide presentation pathway in dendritic cells. Immunol. Lett. 79:97-100.
21. Jackson, D. C., Y. F. Lau, T. Le, A. Suhrbier, G. Deliyannis, C. Cheers, C. Smith, W. Zeng, and L. E. Brown. 2004. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 101:15440-15445.
22. Khanna, K. M., A. J. Lepisto, and R. L. Hendricks. 2004. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol. 25:230-234.
23. Koelle, D. M., and L. Corey. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
24. Kumaraguru, U., M. Gierynska, S. Norman, B. D. Bruce, and B. T. Rouse. 2002. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J. Virol. 76:136-141.
25. Loing, E., M. Andrieu, K. Thiam, D. Schorner, K. H. Wiesmuller, A. Hosmalin, G. Jung, and H. Gras-Masse. 2000. Extension of HLA-A*0201- restricted minimal epitope by N epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J. Immunol. 164:900-907.
26. Lo-Man, R, S. Vichier-Guerre, R. Perraut, E. Deriaud, V. Huteau, L. BenMohamed, O. M. Diop, P. O. Livingston, S. Bay, and C. Leclerc. 2004. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 64:4987-4994.
27. Mikloska, Z., M. Ruckholdt, I. Ghadiminejad, H. Dunckley, M. Denis, and A. L. Cunningham. 2000. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J. Immunol. 164:5167-5176.
28. Moron, G., G. Dadaglio, and C. Leclerc. 2004. New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 25:92-97.
29. Nardin, E. H., J. M. Calvo-Calle, G. A. Oliveira, R. S. Nussenzweig, M. Schneider, J. M. Tiercy, L. Loutan, D. Hochstrasser, and K. Rose. 2001. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 166:481-489.
30. Nesburn, A., T. Ramos, X. Zhu, H. Asgarzadeh, V. Nguyen, and L. BenMohamed. 2005. Local and systemic B-cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23:873-883.
31. Osorio, Y., J. Cohen, and H. Ghiasi. 2004. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Investig. Ophthalmol. Vis. Sci. 45:506-514.
32. Pamonsinlapatham, P., N. Decroix, L. Mihaila-Amrouche, A. Bouvet, and J. P. Bouvet. 2004. Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide. Scand. J. Immunol. 59:504-510.
33. Pialoux, G., H. Gahery-Segard, S. Sennet, H. Poncelet, S. Fournier, L. Gérard, A. Tartar, H. Gras-Masse, J. P. Levy, and J. G. Guillet. 2001. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 13:1239-1249.
34. Richards, C. M., R. Case, T. R. Hirst, T. J. Hill, and N. A. Williams. 2003. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J. Virol. 77:6692-6699.
35. Rosenthal, K. S., H. Mao, W. I. Horne, C. Wright, and D. Zimmerman. 1999. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 17:535-542.
36. Sette, A., B. Livingston, D. McKinney, E. Appella, J. Fikes, J. Sidney, M. Newman, and R. Chesnut. 2001. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29:271-276.
37. Stanberry, L. R. 2004. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11(Suppl. 3):161A-169A.
38. Toka, F. N., C. D. Pack, and B. T. Rouse. 2004. Molecular adjuvants for mucosal immunity. Immunol. Rev. 199:100-112.
39. Vichier-Guerre, S., R. Lo-Man, L. BenMohamed, E. Deriaud, S. Kovats, C. Leclerc, and S. Bay. 2003. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. J. Pept. Res. 62:117-124.
40. Woodland, D. L., and R. W. Dutton. 2003. Heterogeneity of CD4(+) and CD8(+) T cells. Curr. Opin. Immunol. 15:336-342.
41. Zajac, A. J., K. Murali-Krishna, J. N. Blattman, and R. Ahmed. 1998. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr. Opin. Immunol. 10:444-449.
42. Zeng, W., S. Ghosh, Y. F. Lau, L. E. Brown, and D. C. Jackson. 2002. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 169:4905-4912.
43. Zhu, X., T. V. Ramos, H. Gras-Masse, B. E. Kaplan, and L. BenMohamed. 2004. Lipopeptide epitopes extended by Ne-palmitoyl lysine moiety increases uptake and maturation of dendritic cell through a Toll-like receptor 2 pathway and triggers a Th1-dependent protective immunity. Eur. J. Immunol. 34:1142-1149.